INM vs. KA, OBSV, SHPH, ATHE, CHRO, TCBP, WENA, GOVX, TCRT, and BNOX
Should you be buying InMed Pharmaceuticals stock or one of its competitors? The main competitors of InMed Pharmaceuticals include Kineta (KA), ObsEva (OBSV), Shuttle Pharmaceuticals (SHPH), Alterity Therapeutics (ATHE), Chromocell Therapeutics (CHRO), TC Biopharm (TCBP), ANEW Medical (WENA), GeoVax Labs (GOVX), Alaunos Therapeutics (TCRT), and Bionomics (BNOX). These companies are all part of the "pharmaceutical products" industry.
InMed Pharmaceuticals (NASDAQ:INM) and Kineta (NASDAQ:KA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, community ranking, profitability, earnings and analyst recommendations.
Kineta has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -108.02%. InMed Pharmaceuticals' return on equity of -53.42% beat Kineta's return on equity.
In the previous week, InMed Pharmaceuticals had 1 more articles in the media than Kineta. MarketBeat recorded 3 mentions for InMed Pharmaceuticals and 2 mentions for Kineta. InMed Pharmaceuticals' average media sentiment score of 0.56 beat Kineta's score of 0.44 indicating that InMed Pharmaceuticals is being referred to more favorably in the media.
InMed Pharmaceuticals has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500. Comparatively, Kineta has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500.
InMed Pharmaceuticals received 5 more outperform votes than Kineta when rated by MarketBeat users. However, 100.00% of users gave Kineta an outperform vote while only 47.06% of users gave InMed Pharmaceuticals an outperform vote.
Kineta has a consensus target price of $8.00, suggesting a potential upside of 1,144.17%. Given Kineta's higher probable upside, analysts plainly believe Kineta is more favorable than InMed Pharmaceuticals.
20.1% of InMed Pharmaceuticals shares are owned by institutional investors. Comparatively, 30.3% of Kineta shares are owned by institutional investors. 1.4% of InMed Pharmaceuticals shares are owned by insiders. Comparatively, 23.7% of Kineta shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
InMed Pharmaceuticals has higher earnings, but lower revenue than Kineta.
Summary
Kineta beats InMed Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
Get InMed Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for INM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InMed Pharmaceuticals Competitors List
Related Companies and Tools
